Market Place
Sourcing Support
Rakovina Therapeutics Announces 2025 Financials & Corporate
30 Apr 2026 //
GLOBENEWSWIRE
Rakovina Closes $1M Debenture Unit Placement & Debt Settlements
05 Mar 2026 //
GLOBENEWSWIRE
Rakovina Reports Strong Validation After DDR Inhibitors Summit
04 Feb 2026 //
GLOBENEWSWIRE
Rakovina Therapeutics To Attend Partnering Meetings At JPM Week
17 Dec 2025 //
GLOBENEWSWIRE
Rakovina President To Join Expert Panel At DDR Summit
18 Nov 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics to Present at H.C. Wainwright Conference
04 Sep 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Reports Q2 2025 Financials and Corporate
28 Aug 2025 //
GLOBENEWSWIRE
Rakovina, NanoPalm Plan venture for AI-Driven Oncology Therapies
12 Aug 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics and Vancouver Prostate Centre Collaboration
30 Jul 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Grants Stock Options
29 Jul 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Launches Warrant Exercise Incentive Program
24 Jul 2025 //
GLOBENEWSWIRE
Rakovina`s KT-5000AI Program Produces Potent ATR Inhibitor Hits
23 Jul 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Gets DTC Eligibility for US Investor Access
15 Jul 2025 //
GLOBENEWSWIRE
Rakovina Celebrates LifeSciencesBC Award for Variational AI
11 Jul 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Strong H1 Progress, H2 2025 Priorities
30 Jun 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics to Amend Debentures and Warrants
30 Jun 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics` 2025 Annual General Meeting Results
25 Jun 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Share Consolidation Effective Date
20 Jun 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics at BIO International Convention for Partner
12 Jun 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Closes $4.9M Private Placement
06 Jun 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces 2025 Q1 Financial Results
02 Jun 2025 //
GLOBENEWSWIRE
Rakovina Announces Debentureholder Election for Shares
28 May 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Strategic Private Placement
15 May 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Appoints Dr. David Kideckel as CFO
05 May 2025 //
GLOBENEWSWIRE
Rakovina Reveals AI-Discovered Cancer Therapies at AACR 2025
29 Apr 2025 //
GLOBENEWSWIRE
Rakovina appoints Yevgeniy Meshcherekov and David Kideckel
29 Apr 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Congratulates Dr. Artem on AI Innovation
22 Apr 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Reveals Preclinical Data at AACR Forum
25 Mar 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics and Variational AI Strengthen Partnership
26 Feb 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces AI-Driven Cancer Drug Discovery
06 Feb 2025 //
GLOBENEWSWIRE
Rakovina Therapeutics to Participate in BioInnovate UBC Conference
29 Jan 2025 //
GLOBENEWSWIRE
Rakovina Comments On $500B AI Investment And Innovation Impact
22 Jan 2025 //
GLOBENEWSWIRE
Rakovina Reflecting on 2024 Success, Building Momentum for 2025
19 Dec 2024 //
GLOBENEWSWIRE
Rakovina Announces Debentureholder Election for Shares in Debenture
17 Dec 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces 2024 Q2 Financial Results
30 Aug 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Closes Oversubscribed Private Placement
26 Jul 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
22 Jul 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Second Upsizing of Private Placement
19 Jul 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Oversubscribed Private Placement
20 Jun 2024 //
GLOBENEWSWIRE
Rakovina Provides Q1 2024 Financials And Business Update
30 May 2024 //
GLOBENEWSWIRE
Rakovina Debenture Interest Payment: Partial Shares Elected By Debentureholders
24 May 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
23 May 2024 //
GLOBENEWSWIRE
Rakovina Expands AI Research Collaborations
08 May 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics 2023 Results, Corporate Update
26 Apr 2024 //
GLOBENEWSWIRE
Rakovina at AACR Annual Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
01 Apr 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Strategic Pivot to AI
27 Mar 2024 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results
27 Nov 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q2 2023 FYR and Provides Corporate Update
29 Aug 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
28 Jun 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results
31 May 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Closing of $1.5M Convertible Debenture Financing
29 May 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible
01 May 2023 //
GLOBENEWSWIRE
Rakovina Inc. Announces Enhanced Liquidity and Investor Awareness Programs
30 Mar 2023 //
GLOBENEWSWIRE
Rakovina Receives Funding to Accelerate Development of Novel Cancer Therapies
22 Mar 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics Announces Plan to Apply to Extend Warrant Expiry Dates
10 Mar 2023 //
GLOBENEWSWIRE
Rakovina Announces Presentation at the 6th Annual DDR-inhibitors Summit
26 Jan 2023 //
GLOBENEWSWIRE
Rakovina Therapeutics to Present at the Emerging Growth Conference in November
23 Nov 2022 //
GLOBENEWSWIRE
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results
17 Nov 2022 //
GLOBENEWSWIRE
Rakovina Announces Publication Activity Novel Bi-functional PARP-HDAC
14 Nov 2022 //
GLOBENEWSWIRE
